Last edition
News about "Pfizer"
Novo Nordisk Submits Updated Proposal to Acquire Metsera in Multi-Billion-Dollar Deal
Novo Nordisk has confirmed that it has submitted an updated, unsolicited proposal to acquire Metsera, which has been declared superior by Metsera’s board of directors.
Pfizer | 06/11/2025 | By Dineshwori
Pfizer has announced positive topline results from its Phase 3 HER2CLIMB-05 trial evaluating TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a first-line maintenance therapy for patients with HER2-positive (HER2+) metastatic breast cancer (MBC).
Pfizer | 15/10/2025 | By Dineshwori
Pfizer signs Agreement with US Government to Lower Drug Costs for American Patients
Pfizer has voluntarily agreed to implement measures designed to ensure Americans receive comparable drug prices to those available in other developed countries and pricing newly launched medicines at parity with other key developed markets.
Pfizer | 01/10/2025 | By Dineshwori
Pfizer to Acquire Metsera, Expand Obesity and Cardiometabolic Drug Pipeline
Pfizer is set to acquire Metsera, a clinical-stage biopharmaceutical company focused on developing the next generation of medicines for obesity and cardiometabolic diseases.
Pfizer | 23/09/2025 | By Dineshwori
Pfizer, Novartis, Roche Lead Net-Zero Pharma Supply Chain Transition
Europe currently dominates the global net-zero pharma supply chain market supported by strict climate regulations, while Asia-Pacific is the fastest-growing region, spurred by new government-led sustainability policies.
Pfizer | 11/09/2025 | By Dineshwori | 228
DPIIT, Pfizer Ink Partnership to Support MedTech Startups
The Pfizer INDovation programme will empower DPIIT-recognised startups with grants of up to INR 60 lakhs each, along with a tailored 18-month incubation programme delivered by Social Alpha.
<br />
Pfizer | 05/09/2025 | By Dineshwori | 102
Merck, BMS, Pfizer to Be Hit Hard by Looming Patent Cliff: Report Warns
Major pharmaceutical players, including Merck, Bristol Myers Squibb (BMS), Johnson and Johnson, Pfizer, and Novartis, are expected to experience significant revenue losses as several of their blockbuster drugs approach patent expirations, according to a new report by Research and Markets.
Pfizer | 28/07/2025 | By Dineshwori | 289
Pfizer and BioNTech's Updated COVID-19 Vaccine Secures EMA Nod, Awaits Final EU Approval
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Pfizer- BioNTech's LP.8.1-adapted monovalent COVID-19 vaccine in the European Union.
Pfizer | 28/07/2025 | By Dineshwori | 136
The global biologics and biosimilars market is expected to reach approximately USD 600 billion by 2032, expanding at a compound annual growth rate (CAGR) of around 6.33 percent during the forecast period.
Pfizer | 15/07/2025 | By Dineshwori
Pfizer Signs Marketing and Supply Deal with Mylan Pharmaceuticals
Under the terms of the agreement, Pfizer will retain ownership of the brands, while Mylan will be responsible for their marketing and sales within India for a period of five years.
Pfizer | 25/02/2025 | By Aishwarya | 481
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy